|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 14, 2015 ) Global Markets Direct’s, ‘Myocardial Infarction – Pipeline Review, H1 2015’, provides an overview of the Myocardial Infarction’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects.
Complete report on H1 2015 pipeline review of “Sepsis” addiction with 88 market data tables and 16 figures, spread across 338 pages is available at http://www.rnrmarketresearch.com/myocardial-infarction-pipeline-review-h1-2015-market-report.html . (This is a premium report price at US$2000 for a single user PDF license)
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Scope:
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=380711 .
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Reasons to Buy:
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned in This Reports:
• A. Menarini Industrie Farmaceutiche Riunite Srl
• Alligator Bioscience AB
• Amarantus Bioscience Holdings, Inc.
• Angion Biomedica Corp.
• Aprogen, Inc.
• APT Therapeutics, Inc.
• AstraZeneca PLC
• Athersys, Inc.
• Bayer AG
• Bharat Biotech International Limited
• BioLineRx, Ltd.
• Biscayne Pharmaceuticals, Inc.
• Cardio3 BioSciences SA
• Cellmid Limited
• CellProthera
• Compugen Ltd.
• CSL Limited
• FibroGen, Inc.
• Fina Biotech
• Genextra S.p.a.
• GlaxoSmithKline plc
• GliaMed, Inc.
• Hadasit Medical Research Services & Development Ltd
• Human Stem Cells Institute
More reports on Cardiovascular Disease Drugs :
Prasugrel – Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)
Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. ! NOW WITH ‘USA VIEW’!
“The most extensive source of patent information available” Product Portfolio Manager – Dr Reddys Laboratories
“The database is reliable, frequently updated, well-arranged, user friendly.” Director IP – Zentiva k.s
Complete report is available at http://www.rnrmarketresearch.com/prasugrel-patent-extension-and-data-exclusivity-expiry-snapshot-50-countries-market-report.html .
RnR Market Research
Ritesh Tiwari
+ 1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
